Did you know that you can buy products from over 140 different suppliers from us?

Fanconi Anemia, Complementation Group D2 (FANCD2) (N-Term) antibody

Details for Product No. ABIN250523
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms FANCD2, CG17269, CG31192, CG31194, Dmel\\CG17269, dmFANCD2, xfancd2, FA-D2, FA4, FACD, FAD, FAD2, FANCD, 2410150O07Rik, AU015151, BB137857
Epitope
N-Term
(23), (12), (10), (4), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Monkey, Mouse (Murine)
(92), (55), (46), (36), (24), (24), (6)
Host
Rabbit
(87), (14)
Clonality
Polyclonal
Conjugate
Un-conjugated
(4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1)
Application
Western Blotting (WB), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP)
(62), (33), (30), (25), (23), (16), (12), (9), (2), (1), (1), (1)
Pubmed 15 references available
Quantity 0.025 mL
Shipping to United States (Change)
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN250523
Contact our Customer Service for availability and price in your country.
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Human FANCD2 fusion protein (N-terminal fragment).
Specificity This antibody is specific for FANCD2.
Purification Affinity purified
Alternative Name FANCD2
Background Fanconi anemia (FANC) is a human autosomal-recessive cancer susceptibility disordercharacterized by congenital defects, progressive bone marrow failure, and cellularhypersensitivity to mitomycin C (MMC). The FANC subunit D2 protein is vital for cellularresistance to DNA cross-linking and the arrest of DNA synthesis after ionizing radiation. DNA damage activates the monoubiquitination of FANCD2, targeting nuclear focicontaining the BRCA1 protein. Alternate Names: anti-FA4 antibody, anti-FACD antibody, anti-FAD antibody, anti-FAD2 antibody,anti-FANCD antibody, anti-Fanconi Anemia Complementation Group D antibody,anti-Fanconi Pancytopenia Type 4 antibody.
Gene Symbol: FANCD2
Gene ID 2177
UniProt Q9BXW9
Research Area Chromatin and Nuclear Signaling, DNA/RNA
Application Notes By Western blot, this antibody should recognize a band at ~166 kDa (post-translationally modified form). Additional bands may be seen at lower molecular weights. For immunofluorescence it has been tested in human MMC and IR treated MEF cells. This antibody may also be used for Immunoprecipitation and Immunohistochemistry-Paraffin
Recommended dilutions: Immunocytochemistry/Immunofluorescence 1:200-1:500, Immunohistochemistry 2.5-5.0 µg/mL, Immunohistochemistry-Paraffin 2.5-5.0 µg/mL, Immunoprecipitation 1:10-1:500, Western Blot 1:10000-1:20000
Protocol Protocol specific for FANCD2 Antibody Western Blot
1. Proteins are separated on a 7.5 % SDS-PAGE gel.
. Following the protein transfer, the membrane is blocked with TBST + 3 % milk.
. Anti-FANCD2 [cat# NB 100-182] is diluted in blocking buffer and incubated for 1 hour at room temperature, gently shaking.
. The membrane is then washed, 3 times with TBST, 5 minutes each.
. Secondary antibody is incubated for 1 hour at room temperature, gently shaking.
. The membrane is then washed, 3 times with TBST, 5 minutes each.
. Membrane is developed using ECL reagents. Visualization after a 30 second -2 minute exposure. NOTE: HeLa whole cell extracts [cat# NB 800-PC1] were used as positive control for this antibodyImmunoprecipitation 4ul for 1 mg of whole cell extract prepared by lysis in either standard RIPA buffer or a mild buffer composed of 10 mM Tris/HCl pH 8, 150 mM NaCl, 2 mM MgCl2, 0.1 % Triton X-100 + inhibitors.Immunohistochemistry - FFPE sectionsI. DeparaffinizationA. Treat slides with Xylene: 3 changes for 5 minutes each. Drain slides for 10 seconds between changesB. Treat slides with 100 % Reagent Alcohol: 3 changes for 5 minutes each. Drain slides for 10 seconds between changes.II. Quench Endogenous PeroxidaseA. Place slides in peroxidase quenching solution: 15-30 minutes.To Prepare 200 mL of Quenching Solution: Add 3 mL of 30 % Hydrogen Peroxide to 200 mL of Methanol. Use within 4 hours of preparation.B. Place slides in distilled water: 2 changes for 2 minutes each.III. Retrieve Epitopes:A. Preheat Citrate
Restrictions For Research Use only
Format Liquid
Concentration 1.0 mg/mL
Buffer Tris-glycine, 150 mM NaCl, pH 7.5, Sodium Azide
Preservative Sodium azide
Precaution of Use WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
Handling Advice Avoid freeze-thaw cycles
Storage -20 °C
Storage Comment Aliquot and store at -20 °C or -80 °C.
Supplier Images
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) (N-Term) antibody FancD2 colocalizes in vivo with another protein in SiHa cells after cell exposure to IR. Proliferating SiHa cells were exposed to 10 Gy of IR and double -color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) (N-Term) antibody (2) FancD2 colocalizes in vivo with another protein in U2OS cells after cell exposure to IR. Proliferating U2OS cells were exposed to 10 Gy of IR and double -color immunofluorescence staining was performed after 8 h. Images were captured in a Kodak digital image system on a Leica fluorescence microscope.
anti-Fanconi Anemia, Complementation Group D2 (FANCD2) (N-Term) antibody (3) FANCD2 in HeLa WCE using ABIN151329 (lot C).
General Garcia-Higuera, Taniguchi, Ganesan et al.: "Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway." in: Molecular cell, Vol. 7, Issue 2, pp. 249-62, 2001 (PubMed).

McMahon, Sangerman, Goodman et al.: "Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links." in: Biochemistry, Vol. 40, Issue 24, pp. 7025-34, 2001 (PubMed).

Digweed, Rothe, Demuth et al.: "Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia." in: Carcinogenesis, Vol. 23, Issue 7, pp. 1121-6, 2002 (PubMed).

Taniguchi, Garcia-Higuera, Andreassen et al.: "S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51." in: Blood, Vol. 100, Issue 7, pp. 2414-20, 2002 (PubMed).

Sridharan, Brown, Lambert et al.: "Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links." in: Journal of cell science, Vol. 116, Issue Pt 5, pp. 823-35, 2003 (PubMed).

Lensch, Tischkowitz, Christianson et al.: "Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia." in: Blood, Vol. 102, Issue 1, pp. 7-16, 2003 (PubMed).

Taniguchi, Tischkowitz, Ameziane et al.: "Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors." in: Nature medicine, Vol. 9, Issue 5, pp. 568-74, 2003 (PubMed).

Olopade, Wei: "FANCF methylation contributes to chemoselectivity in ovarian cancer." in: Cancer cell, Vol. 3, Issue 5, pp. 417-20, 2003 (PubMed).

Rothfuss, Grompe: "Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway." in: Molecular and cellular biology, Vol. 24, Issue 1, pp. 123-34, 2003 (PubMed).

Donahue, Campbell: "A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts." in: Nucleic acids research, Vol. 32, Issue 10, pp. 3248-57, 2004 (PubMed).

Bekker-Jensen, Lukas, Kitagawa et al.: "Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks." in: The Journal of cell biology, Vol. 173, Issue 2, pp. 195-206, 2006 (PubMed).

Mukhopadhyay, Leung, Hicks et al.: "Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia." in: The Journal of cell biology, Vol. 175, Issue 2, pp. 225-35, 2006 (PubMed).

Dunn, Potter, Rees et al.: "Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light." in: Cancer research, Vol. 66, Issue 23, pp. 11140-7, 2006 (PubMed).

Oda, Hayano, Miyaso et al.: "Hsp90 regulates the Fanconi anemia DNA damage response pathway." in: Blood, Vol. 109, Issue 11, pp. 5016-26, 2007 (PubMed).

Jacquemont, Taniguchi: "Proteasome function is required for DNA damage response and fanconi anemia pathway activation." in: Cancer research, Vol. 67, Issue 15, pp. 7395-405, 2007 (PubMed).

Validation Images
back to top